Trinity Biotech plc — News

- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+  's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates practical value of Trinity Biotech's proprietary multi-sensor wearable biosensor technology beyond glucose-only CGM monitoring - Reinforces differentiation opportunity for CGM+ within the $15 billion1 global CGM market DUBLIN and WILSONVILLE, Ore., July 02, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced clinical study results demonstrating that its next-generation CGM+ wearable biosensor platform has successfully delivered a purpose-built capability to identify nocturnal compression-related false low glucose events, with its differentiated technology addressing a common limitation of conventional continuous glucose monitoring (CGM) systems.

globenewswire.com - 2026-07-02 08:30:00

- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1 DUBLIN and WILSONVILLE, Ore., June 30, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that Trinovium, its recently established subsidiary focused on high-performance liquid cooling solutions for AI data centers, has secured Silver Membership in the Open Compute Project (OCP), providing Trinovium with a platform to directly engage with one of the most influential global ecosystems shaping next-generation data center infrastructure.

globenewswire.com - 2026-06-30 09:00:00

DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.

globenewswire.com - 2026-06-29 15:15:00

- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance computing environments

globenewswire.com - 2026-06-23 07:30:00

– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets

globenewswire.com - 2026-06-16 09:10:00

- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base  - Company announces further operational progress in its Comprehensive Transformation Plan - Company publishes Q4 2025 financial results with revenue broadly in line with previously issued trading update & year-on-year gross margin percentage improvements DUBLIN, May 01, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) (“Trinity” or the “Company”), a commercial‑stage diagnostics and health technology company, today announced the appointment of Jerry Lydon as Head of North America Commercial Operations. Mr. Lydon's appointment represents a deliberate next step as the Company's core diagnostics business transitions from the execution phase of its Comprehensive Transformation Plan toward a sustained focus on building revenue momentum and, importantly, driving profitability from a more efficient and disciplined operating base.

globenewswire.com - 2026-05-01 09:27:00